We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Panel Recommends NDAs for Bacterial Pneumonia, Skin Infections
FDA Panel Recommends NDAs for Bacterial Pneumonia, Skin Infections
An FDA advisory panel voted Wednesday in favor of the safety and efficacy of Paratek’s two NDAs for omadacycline tablets and omadacycline injection as treatments for community-acquired bacterial pneumonia (CAPB) and acute bacterial skin and skin structure infections (ABSSSI).